ML22095A285: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot change)
(StriderTol Bot change)
 
Line 1: Line 1:
{{Adams
#REDIRECT [[IR 05000232/2014001]]
| number = ML22095A285
| issue date = 04/05/2022
| title = 627275-Amendment 24 License 50-23214-01/030-20372 for Diagnostic Health Center of Anchorage, LLC
| author name = Hanson L
| author affiliation = NRC/RGN-IV/DNMS
| addressee name =
| addressee affiliation = NRC/Document Control Desk
| docket = 03020372
| license number = 50-23214-01
| contact person =
| case reference number = License-627275-165144
| document type = License-Approval for MATL Byproduct License (Amend/Renewal/New) DKT 30, 40, 70
| page count = 1
}}
See also: [[see also::IR 05000232/2014001]]
 
=Text=
{{#Wiki_filter:NRC FORM 374                                                                                                                                        PAGE  1  OF 3 PAGES
                                                                      U.S. NUCLEAR REGULATORY COMMISSION                                              Amendment No. 24
                                                                            MATERIALS LICENSE
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I,
Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued
authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s)
and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This
license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and
orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.
                              Licensee                                  In accordance with letter dated                4. Expiration Date: March 31, 2025
                                                                        July 6, 2021
  1. Diagnostic Health Center of Anchorage, LLC
      A wholly owned subsidiary of Alliance HealthCare
      Services
                                                                                                                        5. Docket No.: 030-20372
  2. 4100 Lake Otis Parkway #102                                        3. License No.: 50-23214-01 is                    Reference No.:
      Anchorage, AK 99508                                                  amended in its entirety to read as
                                                                            follows:
  6.  Byproduct, source,              7.  Chemical and/or physical form              8.  Maximum amount that licensee      9.  Authorized use
      and/or special nuclear                                                              may possess at any one time
      material                                                                            under this license
  A.  Any byproduct material          A.  Any                                        A.  As Needed                        A.    For use in uptake, dilution and
      permitted by 10 CFR                                                                                                          excretion studies permitted by 10 CFR
      35.100                                                                                                                      35.100.
  B.  Any byproduct material          B.  Any                                        B.  As Needed                        B.    For use in imaging and localization
      permitted by 10 CFR                                                                                                          studies permitted by 10 CFR 35.200.
      35.200
  C.  Iodine-131                      C.  Any                                        C.  500 millicuries total            C.    Any sodium iodide Iodine-131 use
                                                                                                                                  permitted by 10 CFR 35.300 for which
                                                                                                                                  the patient can be released under the
                                                                                                                                  provisions of 10 CFR 35.75.
  D.  Any byproduct material          D.  Prepackaged Kits                          D.  50 millicuries total              D.    For use in in-vitro studies.
      permitted by 10 CFR
      31.11
 
NRC FORM 374A                                              U.S. NUCLEAR REGULATORY COMMISSION                                  PAGE  2 OF 3 PAGES
                                                License No.: 50-23214-01                    Docket or Reference No.:
          MATERIALS LICENSE                                                                  030-20372
        SUPPLEMENTARY SHEET                    Amendment No. 24
                                                                      CONDITIONS
10. Licensed material may be used only at the licensees facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102,
    Anchorage, Alaska.
11. The Radiation Safety Officer for this license is Kay Kassel, MS, CNMT.
12. Licensed material shall only be used by, or under the supervision of:
    A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
    B. The following individuals are authorized users for the material and medical uses as indicated:
        Authorized Users                          Material and Use
        Marc R. Beck, M.D.                        35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
        Robert L. Bridges, M.D.                  35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the
    minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
 
NRC FORM 374A                                            U.S. NUCLEAR REGULATORY COMMISSION                                PAGE    3  OF 3 PAGES
                                                License No.: 50-23214-01                Docket or Reference No.:
          MATERIALS LICENSE                                                              030-20372
        SUPPLEMENTARY SHEET                    Amendment No. 24
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements,
    representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to
    those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the
    licensees ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory
    Commissions regulations shall govern unless the statements, representations, and procedures in the licensees application and
    correspondence are more restrictive than the regulations.
    A. Application dated October 20, 2014 (ML14336A723)
    B. Letter dated February 16, 2015 with enclosures (ML15061A178)
    C. Letter dated July 6, 2021 (ML21196A052)
                                                                                  FOR THE U.S. NUCLEAR REGULATORY COMMISSION
                                                                                                                      Digitally signed by Latischa M.
                                                                                      Latischa M. Hanson            Hanson
        April 5, 2022                                                                                                Date: 2022.04.05 19:20:39 -05'00'
Date:                                                                            By:
                                                                                      Latischa M. Hanson
                                                                                      Region IV
                                                                                                                                    ML22073A267
}}

Latest revision as of 07:11, 18 November 2024

Redirect to:

Retrieved from "https://kanterella.com/w/index.php?title=ML22095A285&oldid=3730817"